Patents by Inventor Angela Siegling

Angela Siegling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RECOMBINANT PROTEINS OF PARAPOXVIRUS OVIS AND PHARMACEUTICAL COMPOSITIONS THEREFROM
    Publication number: 20190292231
    Abstract: The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.
    Type: Application
    Filed: June 12, 2019
    Publication date: September 26, 2019
    Applicant: AiCuris GmbH & Co. KG
    Inventors: Olaf WEBER, Sonja Maria TENNAGELS, Angela SIEGLING, Tobias SCHLAPP, Andrew Allan MERCER, Stephen Bruce FLEMING, Hans-Dieter VOLK
  • RECOMBINANT PROTEINS OF PARAPOXVIRUS OVIS AND PHARMACEUTICAL COMPOSITIONS THEREFROM
    Publication number: 20170320918
    Abstract: The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.
    Type: Application
    Filed: July 20, 2017
    Publication date: November 9, 2017
    Applicant: AiCuris GmbH & Co. KG
    Inventors: Olaf WEBER, Sonja Maria TENNAGELS, Angela SIEGLING, Tobias SCHLAPP, Andrew Allan MERCER, Stephen Bruce FLEMING, Hans-Dieter VOLK
  • Recombinant proteins of parapdxvirus ovis and pharmaceutical compositions therefrom
    Patent number: 9714272
    Abstract: The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: July 25, 2017
    Assignee: AICURIS GMBH & CO. KG
    Inventors: Olaf Weber, Sonja Maria Tennagels, Angela Siegling, Tobias Schlapp, Andrew Allan Mercer, Stephen Bruce Fleming, Hans-Dieter Volk
  • RECOMBINANT PROTEINS OF PARAPOXVIRUS OVIS AND PHARMACEUTICAL COMPOSITIONS THEREFROM
    Publication number: 20140377297
    Abstract: The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.
    Type: Application
    Filed: September 8, 2014
    Publication date: December 25, 2014
    Inventors: Olaf WEBER, Sonja Maria TENNAGELS, Angela SIEGLING, Tobias SCHLAPP, Andrew Allan MERCER, Stephen Bruce FLEMING, Hans-Dieter VOLK
  • Recombinant proteins of and pharmaceutical compositions therefrom
    Patent number: 8852577
    Abstract: The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: October 7, 2014
    Assignee: AiCuris GmbH & Co. KG
    Inventors: Olaf Weber, Sonja Maria Tennagels, Angela Siegling, Tobias Schlapp, Andrew Allan Mercer, Stephen Bruce Fleming, Hans-Dieter Volk
  • Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom
    Patent number: 8357363
    Abstract: The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.
    Type: Grant
    Filed: June 12, 2002
    Date of Patent: January 22, 2013
    Assignee: Aicuris GmbH & Co. KG
    Inventors: Olaf Weber, Sonja Maria Friederichs, Angela Siegling, Tobias Schlapp, Andrew Allan Mercer, Stephen Bruce Fleming, Hans-Dieter Volk
  • Organ, tissue and cell-specific immuno-therapeutic for chronic viral infections and inflammatory, degenerative and proliferative diseases, in particular of the liver, and for cancer, based on a recombinant parapox virus
    Publication number: 20060008471
    Abstract: The present invention relates to the preparation and use of organ-specific, tissue-specific and/or cell-specific recombinant parapoxvirus ovis as a pathogen-specific and organ-specific, targeted immunotherapeutic agent for chronic viral infections and inflammatory, degenerative and proliferative diseases, in particular of the liver, and cancer.
    Type: Application
    Filed: September 13, 2005
    Publication date: January 12, 2006
    Applicant: Bayer Aktiengesellschaft
    Inventors: Olaf Weber, Angela Siegling, Tobias Schlapp
  • Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom
    Publication number: 20040235721
    Abstract: The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.
    Type: Application
    Filed: June 11, 2004
    Publication date: November 25, 2004
    Inventors: Olaf Weber, Sonja Maria Friederichs, Angela Siegling, Tobias Schlapp, Andrew Allan Mercer, Stephen Bruce Fleming
  • Methods of treating viral infections
    Patent number: 6685950
    Abstract: The present invention relates to the use of strains of Parapoxvirus ovis as immunotherapeutic agents for immunodeficiencies of an infectious or non-infectious nature, and to the use of strains of Parapoxvirus ovis for treating tumor diseases and viral infections, and diseases which accompany them, and the use of strains of Parapoxvirus ovis for producing medicaments for use in humans and animals.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: February 3, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Olaf Weber, Tobias Schlapp, Angela Siegling, Andreas Knorr, Claudia Hirth-Dietrich, Gudrun Theiss
  • Use of strains of parapoxvirus ovis against organ fibrosis
    Patent number: 6632647
    Abstract: The present invention relates to the use, in humans, of inactivated parapoxviruses for the prophylaxis and treatment of diseases which are accompanied by an increased deposition of collagen, with it being possible for both internal organs, such as the liver, and the skin and its appended structures, to be affected. The invention relates, in particular, to liver fibrosis and/or liver cirrhosis consequent upon virus hepatitis, or to ethanol-induced liver diseases and to cystic fibrosis.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: October 14, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Claudia Hirth-Dietrich, Tobias Schlapp, Angela Siegling, Andreas Knorr, Olaf Weber, Gudrun Theiss
  • Use of strains of parapoxvirus ovis for producing antiviral medicaments and medicaments against cancer
    Publication number: 20030021769
    Abstract: The present invention relates to the use of strains of Parapoxvirus ovis as immunotherapeutic agents for immunodeficiencies of an infectious or non-infectious nature, and to the use of strains of Parapoxvirus ovis for treating tumor diseases and viral infections, and diseases which accompany them, and the use of strains of Parapoxvirus ovis for producing medicaments for use in humans and animals.
    Type: Application
    Filed: July 11, 2001
    Publication date: January 30, 2003
    Inventors: Olaf Weber, Tobias Schlapp, Angela Siegling, Andreas Knorr, Claudia Hirth-Dietrich, Gudrun Theiss
  • Use of strains of parapoxvirus ovis against organ fibrosis
    Publication number: 20020076418
    Abstract: The present invention relates to the use, in humans, of inactivated parapoxviruses for the prophylaxis and treatment of diseases which are accompanied by an increased deposition of collagen, with it being possible for both internal organs, such as the liver, and the skin and its appended structures, to be affected. The invention relates, in particular, to liver fibrosis and/or liver cirrhosis consequent upon virus hepatitis, or to ethanol-induced liver diseases and to cystic fibrosis.
    Type: Application
    Filed: July 11, 2001
    Publication date: June 20, 2002
    Inventors: Claudia Hirth-Dietrich, Tobias Schlapp, Angela Siegling, Andreas Knorr, Olaf Weber, Gudrun Theiss
  • 3-(mercaptoalkyl)quinazoline
    Patent number: 5306721
    Abstract: A compound or its tautomer of Formula I, ##STR1## wherein R.sup.1 is hydrogen, a 6-methyl, 6-fluoro, 6-chloro, 6-bromo, or 6,7-dimethoxy residue,R.sup.2 is hydrogen, or a methyl residue,and n is 1 or 2,and tautomers and their pharmaceutically acceptable alkali, or ammonium salts.
    Type: Grant
    Filed: August 2, 1993
    Date of Patent: April 26, 1994
    Assignee: Arzneimittelerk Dresden G.m.b.H.
    Inventors: Siegfried Leistner, Michael Gutschow, Karl Drossler, Helmut Vieweg, Gunther Wagner, Thomas Strohscheidt, Dieter Lohmann, Gunter Laban, Herwart Ambrosius, Angela Siegling